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Abstract 
During the period of neutropenia induced by
chemotherapy,  patients  have  a  high  risk  of
infection. The use of antibiotic prophylaxis to
reduce  neutropenia-related  complications  in
patients with cancer is still disputed. Recent
meta-analysis and clinical trials demonstrated
that  antibiotic  prophylaxis  with  quinolones
reduces febrile episodes, bacterial infections
and mortality in adult oncological patients with
neutropenia  induced  by  chemotherapy  in
acute  leukaemia.  In  paediatric  patients,  the
only  randomized,  double-blind,  prospective
study  until  now  suggests  that  amoxicillin/
clavulanate may represent an effective prophy-
lactic treatment in reducing fever and infec-
tions in oncological children with neutropenia,
with  an  efficacy  that  is  statistically  demon-
strated only in patients with acute leukaemia.
Considering the risk of resistances, antibiotic-
prophylaxis  should  be  used  only  in  selected
patients.
Introduction
During the period of neutropenia induced by
chemotherapy,  patients  have  a  high  risk  of
infections, with a risk-rate related to the level
and duration of neutropenia.1 Bacterial infec-
tions,  proved  in  a  minority  of  cases,  are  a
major  cause  of  disease  and  death  in  neu-
tropenic  patients,  with  some  differences
according to the aggressiveness of chemother-
apy.2,3 The  use  of  antibiotic  prophylaxis  to
reduce neutropenia-related infectious compli-
cations in patients with cancer, mostly used in
adults,  is  still  disputed.  These  antimicrobial
agents are given to patients at the beginning
of neutropenia, without fever or other signs of
infection.4 Neutropenia  is  defined  as  an
absolute neutrophil count lower than 500/mmc
or under 1.000/mmc if rapidly decreasing.5 The
risk is higher if neutropenia lasts longer than
7 days. Fever is defined by body temperature
equal to or higher than 38.5°C or a tempera-
ture of 38°C lasting for more than an hour or
38°C or more measured at least twice in 12
hours.5,6
Methods
The terms neutropenia & similar, antibiotic
& similar, prophylaxis & similar, cancer & sim-
ilar,  fever &  similar    were  crossed  in  the
Cochrane  Library,  MEDLINE  and  EMBASE
from January 1980 to October 2010. 
Results
Considering that 80% of infections in neu-
tropenic patients originate from endogenous
bacterial  flora,  and  about  half  of  these  are
acquired  in  the  hospital,7 the  first  approach
was the reduction of intestinal flora through
the  use  of  non-absorbable  antibiotics.
Intestinal decontamination was either total or
partial,  if  anaerobic  flora  was  preserved.
Antibiotics mostly used were gentamicin, van-
comycin,  colistin  or  neomycin/polymyxin.8
However, a poor patient compliance associated
with the risk of resettlement by opportunistic
or resistant bacteria led to the failure of the
prophylaxis.9 Selective  decontamination
required careful monitoring of the intestinal
flora.  Afterwards  the  drug  of  choice  became
TMP-SMX, frequently used in association with
nystatin or amphotericin B, even if it some-
times lengthened neutropenia.10 However the
administration  of  TMP-SMX  was  a  systemic
prophylaxis, as far as it is an adsorbable antibi-
otic.  Fluoroquinolones  are  interesting  drugs
for oral prophylaxis, due to their bioavailabili-
ty, wide antibacterial spectrum, sparing of the
anaerobic intestinal flora, bactericide action,
good tolerance and absence of myelosuppres-
sive effect.11 However, their use is contraindi-
cated  for  prophylaxis  in  patients  under  18
years of age because of their possible interfer-
ence with osteocartilagineous development.
Guidelines  from  the  Infectious  Diseases
Society  of  America  (IDSA)  in  2002  recom-
mended the use of antibiotic prophylaxis for a
period as short as possible and in a small num-
ber of patients, in order to avoid the risk of
ddeveloping bacterial resistance and beacuse
of the unproven reduction in mortality despite
the decreased rate of fever episodes.5 However
some meta-analysis and clinical trials showed
that  prophylaxis  with  fluoroquinolones
reduces fever episodes, clinically and microbi-
ologically  proven  bacterial  infections,  infec-
tion-related  and  overall  mortality  in  adult
patients  with  acute  leukaemia.2,12,13 A  large
clinical  trial  in  adult  patients  with  solid
tumours  undergoing  standard  chemotherapy
did  not  show  the  same  results.14 Guidelines
from  ECIL  (European  Conference  on
Infections  in  Leukaemia)  and  NCCN  (US-
National Comprehensive Cancer Network) rec-
ommend prophylaxis with quinolones in adult
patients  undergoing  chemotherapy  for  acute
leukaemia.15,16 According to other Authors, pro-
phylaxis with quinolones should also be con-
sidered in patients with solid tumour or lym-
phoma at the first block of chemotherapy since
it  is  frequently  associated  with  a  4°-degree
neutropenia.17-19
In paediatric patients, the only randomized,
double-blind  2-year  multicentric  AIEOP
(Italian  Association  of  Pediatric  Hematology
and Oncology) prospective study on 173 chil-
dren  suggested  that  amoxicillin/clavulanate
may be an effective prophylactic treatment in
reducing fever and infections in neutropenic
children with cancer, although its efficacy has
been  statistically  demonstrated  only  in
patients with acute leukaemia and lymphoma.
In the general population a clinically signifi-
cant reduction (12%) in fever and infections
was observed, comparing to the placebo group,
although not statistically significant. Authors
concluded that, due to the risk of developing
resistances,  antibiotic  prophylaxis  should  be
used  with  caution  in  a  selected  group  of
patients  and  for  short  periods  of  time.20
Another paediatric study assessed the use of
ciprofloxacin  in  69  children  with  acute  lym-
phoblastic leukaemia during reinduction phas-
es, observing a statistically significant reduc-
tion in the incidence of Gram-negative bacter-
aemias and related admissions to the hospital;
however  the  design  of  the  study  considered
previous patients as control group.21 A retro-
spective study conducted by the St. Jude group
on  antibiotic  prophylaxis  in  78  consecutive
paediatric  patients  with  acute  myeloid
leukaemia undergoing chemotherapy showed
a significant reduction in incidence and mor-
tality  by  septicaemia  after  prophylaxis  with
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intravenous  cefepime  or  intravenous  van-
comycin associated with oral ciprofloxacin.4
There are few data on what concerns repeat-
ed neutropenic periods in the same patients.
The positive effect of antibacterial prophylaxis
reported  in  a  meta-analysis  considered  ran-
domized trials including only one neutropenic
period  per  patient.2 This  beneficial  effect  of
prophylaxis  may  disappear  in  patients  with
repeated  neutropenic  periods  as  shown  by
Castagnola3,20and Cullen.14In order to evaluate
the efficacy of repeated cycles of antibiotic pro-
phylaxis,  the  number  of  multicenter  clinical
trials with a very large number of oncological
patients should be increased.
The prolonged administration of wide spec-
trum antibiotics can cause either the onset of
bacterial resistance and toxicity. The onset of
resistant strains is a justified concern, and has
been  reported  by  centres  using  prophylaxis
with fluoroquinolones.22-24 However a large and
recent meta-analysis was not able to demon-
strate  a  significant  increase  in  colonization
and  infections  caused  by  fluoroquinolone-
resistant bacteria in patients undergoing pro-
phylaxis.25 However these results are limited
by the lack of data reported in trials: in less
than half of the studies microbiologic surveil-
lance was assessed and data on resistant bac-
teria colonization were reported; less than a
third reported data on quinolone-resistant bac-
teria  infections.  Observation  length  was  not
prolonged  enough  to  properly  evaluate  the
effect of antibiotic prophylaxis on resistances.
Therefore, at the moment, long-term effects of
antibiotic prophylaxis on microbiologic resist-
ances are still unknown.12,26
Discussion
There  are  some  patient  groups  that  may
benefit from antibiotic prophylaxis. However,
the wide and prolonged use of antibiotic pro-
phylaxis can lead to the onset of resistant bac-
teria,  nullifying  the  effect  of  prophylaxis.
Therefore, antibiotic prophylaxis in pediatric
patients with cancer should be used only in
selected cases of acute leukaemia, with amox-
icillin/clavulanate (at a dose of  25 mg/kg  twice
a  day),  at  the  end  of  chemotherapy  blocks,
since  quinolones  are  contraindicated  in
patients under 18 years of age. The choice of a
prophylaxis policy for patients at higher risk of
infections requires the adoption or the imple-
mentation  of  a  microbiological  surveillance
program.
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